{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '5. Off-label use: Situations where an IMP is intentionally used for a medical purpose not in', 'accordance with the authorized product information.', \"6. Occupational exposure: Exposure to an IMP, as a result of one's professional or non-\", 'professional occupation.', '7. Breastfeeding: Suspected adverse reactions that occur in infants following exposure to a', 'medicinal product from breast milk.', '7.5.', 'Clinical Laboratory Tests', 'All clinical laboratory test results outside of the reference range will be judged by the', 'investigator as belonging to one of the following categories:', 'abnormal and not clinically significant', 'abnormal and clinically significant', 'The clinical significance of the laboratory values will be evaluated by the criteria described in', 'the laboratory manual and by the judgement of the investigator. A laboratory test result that is', 'judged by the investigator as clinically significant will be recorded both on the source', 'documentation and the CRF as an adverse event, and monitored as described in Section 7.1.2. An', 'event may include a laboratory or diagnostic test abnormality (once confirmed by repeated', 'testing) that results in the withdrawal of the patient from the study, the temporary or permanent', 'cessation of IMP or medical treatment, or further diagnostic work-up. Abnormal laboratory tests', 'can be repeated without approval from the medical monitor. (Note: Abnormal laboratory or', 'diagnostic test results at the screening visit that preclude a patient from entering the study or', 'receiving IMP are not considered adverse events.)', '7.5.1.', 'Serum Chemistry, Hematology, and Urinalysis', 'Clinical laboratory tests (eg, serum chemistry, hematology, urinalysis) will be performed at the', 'time points detailed in Table 1. Clinical laboratory tests will be performed using the central', 'laboratory. Specific laboratory tests to be performed are provided in Table 4.', '89']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Table 4:', 'Clinical Laboratory Tests', 'Serum Chemistry', 'Hematology', 'Urinalysis', 'calcium', 'hemoglobin', 'protein', 'phosphate', 'hematocrit', 'glucose', 'sodium', 'red blood cell (RBC) count', 'ketones', 'potassium', 'mean cell volume', 'blood (hemoglobin)', 'chloride', 'platelet count', 'pH', 'creatinine', 'white blood cell (WBC) count, and', 'specific gravity', 'glucose', 'differential count', 'microscopic', 'magnesium', '-', 'absolute neutrophil', '-', 'bacteria', 'count (ANC)', 'blood urea nitrogen (BUN)', '-', 'RBCs', 'total cholesterol', '- polymorphonuclear leukocytes', '-', 'WBCs', '(neutrophils)', 'uric acid', '-', 'casts', '-', 'lymphocytes', 'alanine aminotransferase (ALT)', '-', '-', 'eosinophils', 'crystals', 'aspartate aminotransferase (AST)', '-', 'monocytes', 'lactate dehydrogenase (LDH)', '-', 'basophils', 'alkaline phosphatase (ALP)', 'bicarbonate or carbon dioxide', 'total protein', 'albumin', 'total bilirubin', 'direct bilirubin', '7.5.2.', 'Other Clinical Laboratory Tests', '7.5.2.1.', 'Human Chorionic Gonadotrophin Test', 'Human chorionic gonadotrophin tests in urine or serum will be performed for all females who', 'are postmenarchal or >12 years of age as detailed in Table 1, and if clinically indicated. Any', 'female patient who becomes pregnant during the study will be withdrawn. Procedures for', 'reporting the pregnancy are provided in Section 7.3.', '7.5.2.2.', 'Urine Drug Screen', 'A UDS will be performed at time points specified in Table 1. The UDS detects the presence of', 'drugs prohibited according to the laboratory manual. If a given parameter cannot be tested using', \"urine, an alternative matrix (eg, serum) may be considered acceptable. The sponsor's medical\", 'expert must be made aware in advance of, and provide approval for, drug screen parameters to', 'which this will apply.', 'A positive result for any of the specified drugs or their metabolites, without medical explanation,', 'will preclude the patient from enrollment or continued participation in the study.', '90']\n\n###\n\n", "completion": "END"}